Wellington Partners

Orcan Energy AG, founded in 2008 and based in Munich, Germany, specializes in energy solutions that convert waste heat into electricity using Organic Rankine Cycle (ORC) technology. The company develops, manufactures, and sells ORC modules designed for industries that can utilize waste heat generated from industrial processes, traffic, and distributed energy systems. Orcan Energy's products include the PACK 20.30, which converts both exhaust gas and cooling water heat into grid-compatible electricity, and the PACK 05.15, suitable for low-temperature applications with input powers of 180 kWth. Its innovative technology has a wide range of applications, including marine, biogas, and mobile platforms such as trucks and construction machinery. As a leader in waste heat recovery technology, Orcan Energy has received support from various government initiatives and institutions, enhancing its ability to bring this technology to the mass market. The company operates as a subsidiary of E.ON SE.

Carisma Therapeutics is a biotechnology company focused on developing innovative cellular immunotherapies to treat solid tumors. Founded in 2016 and based in Philadelphia, Pennsylvania, the company specializes in creating CAR macrophages, which utilize chimeric antigen receptor technology and adoptive cell transfer. This approach aims to enhance cancer treatment by enabling macrophages to infiltrate solid tumor microenvironments, thereby providing robust cellular immunotherapy options for patients. Carisma leverages advancements in macrophage biology and engineering to improve therapeutic outcomes in oncology.

ImCheck Therapeutics SAS is a biotechnology company incorporated in 2015 and based in Marseille, France. The company specializes in designing and developing immunotherapeutics that target the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. With a primary focus on immuno-oncology, ImCheck Therapeutics develops immunomodulatory antibodies aimed at treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company is dedicated to addressing severe unmet medical needs through its innovative approach to cancer treatment and the development of next-generation immunotherapeutics.

Cayaba Care is a maternal health company offering community-based clinical services via technology-enabled multidisciplinary care teams.

SidekickHealth is a digital therapeutics company focused on preventing and managing chronic diseases. It leverages behavioral economics, gamification, and artificial intelligence to create engaging experiences that facilitate behavior change and enhance health and well-being. The company collaborates with pharmaceutical companies and other organizations to develop personalized lifestyle change programs aimed at improving health outcomes and treatment adherence. Additionally, SidekickHealth connects clinical experts with patient communities and provides data insights to address significant health challenges. Its lifestyle companion app serves as a tool to support individuals on their health journeys.

iOmx Therapeutics focuses on the development of first-in-class cancer therapeutics addressing novel immune checkpoint modulators on tumor cells. By systematically screening human tumor cells, the Company has already identified a number of novel targets and analyzed their mode of action. The Company was founded on the successful concept of cancer immune-checkpoint therapy, which works by breaking down the inherent resistance mechanisms of tumors against immune attack. Immune resistance of tumors is often mediated by cell surface molecules that stimulate immune-inhibitory receptors on T cells. Reactivating the host immune response by neutralizing these negative interactions is the idea behind cancer immune-checkpoint therapy.

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

Automattic is the company behind WordPress.com and WordPress.com VIP, the cloud version of WordPress. Automattic hosts and supports all WordPress.com sites ensuring that there is continuous and strategic development of the software available to its users. Automattic also supports WordPress.com VIP, a premium service designed for large-scale enterprises. WordPress.com VIP combines the benefits of WordPress.com and the ability to run custom code. In addition, WordPress.com VIP offers companies a robust CMS and 24/7 service.

Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

UroMems SAS, founded in 2011 and based in Grenoble, France, specializes in the design, development, and commercialization of implantable medical devices. The company has created the MyoElectroMechanical System, an electronic artificial urinary sphincter (eAUS) aimed at treating severe urinary incontinence. This innovative device functions by increasing urethral pressure during physically demanding activities and decreasing it when such activities are not taking place, thereby addressing a significant clinical need that affects patients' quality of life. UroMems is dedicated to providing solutions that target specific health challenges faced by individuals with this condition.

EGenesis Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in New York. Founded in 2015, the company specializes in gene editing and genome engineering, focusing on the development of human-compatible organs, tissues, and cells for transplantation. EGenesis employs advanced gene editing techniques to create transplantable cells and solid organs, specifically targeting therapeutic applications in kidney and islet cell transplantation. By leveraging its innovative platform, the company aims to transform the field of organ transplantation, providing safe and effective solutions for patients with life-threatening diseases globally.

Carisma Therapeutics is a biotechnology company focused on developing innovative cellular immunotherapies to treat solid tumors. Founded in 2016 and based in Philadelphia, Pennsylvania, the company specializes in creating CAR macrophages, which utilize chimeric antigen receptor technology and adoptive cell transfer. This approach aims to enhance cancer treatment by enabling macrophages to infiltrate solid tumor microenvironments, thereby providing robust cellular immunotherapy options for patients. Carisma leverages advancements in macrophage biology and engineering to improve therapeutic outcomes in oncology.

Koa Health is digital wellbeing and therapeutics solutions combine the latest clinical research and breakthrough technologies. It delivers mental health support that is accessible, personalized, and effective across a range of conditions. They create digital tools and resources for mental health that encompass prevention, prediction, and treatment.

Carisma Therapeutics is a biotechnology company focused on developing innovative cellular immunotherapies to treat solid tumors. Founded in 2016 and based in Philadelphia, Pennsylvania, the company specializes in creating CAR macrophages, which utilize chimeric antigen receptor technology and adoptive cell transfer. This approach aims to enhance cancer treatment by enabling macrophages to infiltrate solid tumor microenvironments, thereby providing robust cellular immunotherapy options for patients. Carisma leverages advancements in macrophage biology and engineering to improve therapeutic outcomes in oncology.

IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer.

Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.

Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, specializing in monoclonal antibody therapies aimed at treating sepsis and related conditions. Founded in 2009, the company focuses on developing its lead product candidate, Adrecizumab, a first-in-class humanized monoclonal antibody that targets Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. Adrecizumab is designed to address life-threatening situations characterized by increased vascular leakage, congestion, and shock, with primary indications including sepsis, septic shock, and acute heart failure. Adrenomed's innovative approach integrates its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker to identify suitable patients for treatment. The company boasts a robust intellectual property portfolio, with patents granted in major markets, securing its business position in the competitive biopharmaceutical landscape.

Koa Health is digital wellbeing and therapeutics solutions combine the latest clinical research and breakthrough technologies. It delivers mental health support that is accessible, personalized, and effective across a range of conditions. They create digital tools and resources for mental health that encompass prevention, prediction, and treatment.

SidekickHealth is a digital therapeutics company focused on preventing and managing chronic diseases. It leverages behavioral economics, gamification, and artificial intelligence to create engaging experiences that facilitate behavior change and enhance health and well-being. The company collaborates with pharmaceutical companies and other organizations to develop personalized lifestyle change programs aimed at improving health outcomes and treatment adherence. Additionally, SidekickHealth connects clinical experts with patient communities and provides data insights to address significant health challenges. Its lifestyle companion app serves as a tool to support individuals on their health journeys.

UiPath Inc. specializes in developing robotic process automation (RPA) software for enterprises, aiming to enhance operational efficiency through intelligent process automation. The UiPath platform enables organizations to discover automation opportunities, build and manage automations at scale, and optimize processes using artificial intelligence. Its offerings include tools such as UiPath Studio for designing automation processes, UiPath Orchestrator for managing enterprise tasks, and various robots for executing these processes across multiple applications. UiPath serves a diverse range of industries, including finance, healthcare, insurance, telecommunications, and manufacturing, by automating tasks such as claims processing, employee onboarding, and customer service. Founded in 2005, the company is headquartered in New York City, with additional offices in several global locations, including London, Bucharest, and Tokyo.

Polares Medical S.A. is a medical device company based in Ecublens, Switzerland, with an additional office in Palo Alto, California. The company specializes in developing innovative solutions for patients suffering from mitral valve regurgitation. Its flagship product features a unique trans-catheter mitral valve system that facilitates the replacement of the posterior leaflet with a prosthetic leaflet. This design enables physicians to perform hemi-replacements of the mitral valve, improving coaptation with the native anterior leaflet and offering a less invasive treatment option for patients.

UroMems SAS, founded in 2011 and based in Grenoble, France, specializes in the design, development, and commercialization of implantable medical devices. The company has created the MyoElectroMechanical System, an electronic artificial urinary sphincter (eAUS) aimed at treating severe urinary incontinence. This innovative device functions by increasing urethral pressure during physically demanding activities and decreasing it when such activities are not taking place, thereby addressing a significant clinical need that affects patients' quality of life. UroMems is dedicated to providing solutions that target specific health challenges faced by individuals with this condition.

SIRS Therapeutics operates as a therapeutics company.

ImCheck Therapeutics SAS is a biotechnology company incorporated in 2015 and based in Marseille, France. The company specializes in designing and developing immunotherapeutics that target the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. With a primary focus on immuno-oncology, ImCheck Therapeutics develops immunomodulatory antibodies aimed at treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company is dedicated to addressing severe unmet medical needs through its innovative approach to cancer treatment and the development of next-generation immunotherapeutics.

EGenesis Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in New York. Founded in 2015, the company specializes in gene editing and genome engineering, focusing on the development of human-compatible organs, tissues, and cells for transplantation. EGenesis employs advanced gene editing techniques to create transplantable cells and solid organs, specifically targeting therapeutic applications in kidney and islet cell transplantation. By leveraging its innovative platform, the company aims to transform the field of organ transplantation, providing safe and effective solutions for patients with life-threatening diseases globally.

STipe Therapeutics focuses on harnessing the innate immune system to battle cancer. The company has developed first-in-class drugs targeting intracellular protein-protein interactions of the STING Pathway; a major driver of innate immunity, and regulator of tumorigenesis and autoimmune disorders. The company has identified and validated compounds that sensitizes the STING pathway and by this modulates the tumor microenvironment to support a potent anti-tumoral response.

Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

AMBOSS is a medical technology company with offices in New York, Berlin and Cologne. Its knowledge platform has fundamentally changed the way medical know-how is acquired and utilized at the point-of-care. Students use the interactive library and high-yield question bank for general study and exam preparation, while doctors rely on AMBOSS to make effective clinical decisions guided by evidence-based recommendations. Founded in 2012 by doctors for doctors, the company’s international team has grown to over 200 physicians, scientists and software engineers, all striving to better serve doctors around the world. Today, more than half a million healthcare professionals in over 180 countries rely on AMBOSS.

Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company specializes in developing internal drug discovery programs focused on G-protein coupled receptors (GPCRs) to address unmet medical needs. Utilizing its proprietary CONFO® technology, Confo Therapeutics stabilizes inherently unstable functional conformations of GPCRs, providing a robust starting point for drug discovery. This approach reveals previously inaccessible structural features of these receptors, facilitating the identification of novel agonists that enhance therapeutic interventions.

Keeping technology at the core, Zinka Logistics is redefining the logistics landscape of India, making it reliable and efficient. Our comprehensive approach to problems creates impact on the entire ecosystem of transportation, which stitches across large number of livelihoods. The transportation sector is ripe for a revolution, and Zinka Logistics marks the beginning.

UiPath Inc. specializes in developing robotic process automation (RPA) software for enterprises, aiming to enhance operational efficiency through intelligent process automation. The UiPath platform enables organizations to discover automation opportunities, build and manage automations at scale, and optimize processes using artificial intelligence. Its offerings include tools such as UiPath Studio for designing automation processes, UiPath Orchestrator for managing enterprise tasks, and various robots for executing these processes across multiple applications. UiPath serves a diverse range of industries, including finance, healthcare, insurance, telecommunications, and manufacturing, by automating tasks such as claims processing, employee onboarding, and customer service. Founded in 2005, the company is headquartered in New York City, with additional offices in several global locations, including London, Bucharest, and Tokyo.

SNIPR Biome ApS, established in 2017 and located in Copenhagen, Denmark, is a biotech company focused on developing innovative treatments for microbial diseases using CRISPR technology. The company aims to transform the management of these diseases by employing advanced techniques to manipulate the bacterial CRISPR machinery, enabling the selective targeting and elimination of harmful bacteria in living organisms. This approach provides healthcare professionals with targeted therapeutic options that can effectively address bacterial infections based on specific DNA sequences, representing a significant advancement in the field of microbiome health.

Import.io Ltd is a SaaS company that specializes in Web Data Integration, enabling users to transform extensive web data into structured, machine-readable formats. Founded in 2012 and headquartered in London, with an additional office in Los Gatos, California, the company offers a suite of products including Import.io Extract for automated web extraction, Import.io Insights for data monitoring and visualization, Import.io API for system integration, and Import.io Transform for data formatting. Its solutions support various applications such as competitor price monitoring, MAP compliance, product matching, and customer sentiment analysis. Import.io serves over 850 clients by providing high-quality web data from millions of online sources, thereby enhancing business insights and competitive advantages.

Social network and utility app for youth soccer players who use Tonsser every week to keep track of their stats, improve their player rating, be inspired on how to improve and engage with their community.

Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, specializing in monoclonal antibody therapies aimed at treating sepsis and related conditions. Founded in 2009, the company focuses on developing its lead product candidate, Adrecizumab, a first-in-class humanized monoclonal antibody that targets Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. Adrecizumab is designed to address life-threatening situations characterized by increased vascular leakage, congestion, and shock, with primary indications including sepsis, septic shock, and acute heart failure. Adrenomed's innovative approach integrates its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker to identify suitable patients for treatment. The company boasts a robust intellectual property portfolio, with patents granted in major markets, securing its business position in the competitive biopharmaceutical landscape.

Sphingotec GmbH, founded in 2002 and located in Brandenburg, Germany, specializes in the development of innovative biomarkers aimed at the diagnosis, prediction, and monitoring of acute medical conditions. Their focus includes critical areas such as acute heart failure, acute kidney injury, and circulatory shock, providing essential tools for healthcare professionals in managing these serious health issues. The company’s advancements in biomarker technology contribute significantly to improving patient outcomes in acute medical scenarios.

Polares Medical S.A. is a medical device company based in Ecublens, Switzerland, with an additional office in Palo Alto, California. The company specializes in developing innovative solutions for patients suffering from mitral valve regurgitation. Its flagship product features a unique trans-catheter mitral valve system that facilitates the replacement of the posterior leaflet with a prosthetic leaflet. This design enables physicians to perform hemi-replacements of the mitral valve, improving coaptation with the native anterior leaflet and offering a less invasive treatment option for patients.

Carisma Therapeutics is a biotechnology company focused on developing innovative cellular immunotherapies to treat solid tumors. Founded in 2016 and based in Philadelphia, Pennsylvania, the company specializes in creating CAR macrophages, which utilize chimeric antigen receptor technology and adoptive cell transfer. This approach aims to enhance cancer treatment by enabling macrophages to infiltrate solid tumor microenvironments, thereby providing robust cellular immunotherapy options for patients. Carisma leverages advancements in macrophage biology and engineering to improve therapeutic outcomes in oncology.

TRiCares is a medical device company, devoted to developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgitation.

Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.

Heliatek GmbH, based in Dresden, Germany, specializes in the development and production of organic solar films and photovoltaic cells. Its flagship product, HeliaSol, is an organic photovoltaics (OPV) solution that can be applied to various surfaces, making it suitable for building retrofitting, automotive applications, and other innovative projects. Heliatek caters to the building and construction material sector, as well as automotive manufacturers, offering tailored products like HeliaFilm for integration into façade and roofing systems. The company is recognized as a leader in organic photovoltaics, leveraging its ultra-light and flexible technology to provide sustainable energy solutions. Established in 2006, Heliatek has formed strategic partnerships with companies such as AGC Glass Europe and Reckli China, and it employs around 160 people across its facilities in Germany. The research and development of its technologies have received support from the Free State of Saxony, the Federal Republic of Germany, and the European Union.

GLO AB is a company dedicated to developing and commercializing advanced LED display products utilizing nanotechnology, with its origins rooted in over a decade of research at Lund University. Founded in 2005 and headquartered in Lund, Sweden, GLO also operates a facility in Sunnyvale, California, where it conducts research and pilot fabrication. The company specializes in direct-emitting red, green, and blue microLED products, catering to various sectors including displays, illumination, and automotive applications. GLO's innovative technology allows for the creation of efficient and stable RGB emitters from a single material system, addressing limitations of traditional LED technology. This breakthrough enables superior color stability and the potential for high-quality white LEDs without phosphor conversion. With over 175 patents in the US, Europe, and Asia, GLO is focused on strengthening its intellectual property and advancing its position in the LED market, particularly in fast-growing regions such as Asia.

Social network and utility app for youth soccer players who use Tonsser every week to keep track of their stats, improve their player rating, be inspired on how to improve and engage with their community.

Dalia Research GmbH, founded in 2013 and based in Berlin, Germany, specializes in developing online software solutions for market and opinion research. The company offers a product called Samplive, which facilitates smart data collection through various applications, mobile websites, and social media platforms. Dalia operates in over 100 countries, utilizing the app economy and advanced data science techniques to distribute millions of micro-surveys worldwide. This approach enables the collection and analysis of real-time data on consumer attitudes, public opinion, and market trends. With a diverse team from 19 different countries, Dalia Research aims to generate insights that enhance the understanding of global audiences.

At Latana, we believe there is a better way to do brand tracking. We believe that brand and marketing leaders no longer have to base campaigns on guesswork, spending trillions and not sure at the end if it was worth it. We are passionate about bringing reliable data to the world of brand, finally providing a platform for brand marketing similar to what Google Analytics has been providing for other marketing channels for years. We unravel one of the least understood areas of marketing so you don't have to. Latana is here to help you grow.

GLO AB is a company dedicated to developing and commercializing advanced LED display products utilizing nanotechnology, with its origins rooted in over a decade of research at Lund University. Founded in 2005 and headquartered in Lund, Sweden, GLO also operates a facility in Sunnyvale, California, where it conducts research and pilot fabrication. The company specializes in direct-emitting red, green, and blue microLED products, catering to various sectors including displays, illumination, and automotive applications. GLO's innovative technology allows for the creation of efficient and stable RGB emitters from a single material system, addressing limitations of traditional LED technology. This breakthrough enables superior color stability and the potential for high-quality white LEDs without phosphor conversion. With over 175 patents in the US, Europe, and Asia, GLO is focused on strengthening its intellectual property and advancing its position in the LED market, particularly in fast-growing regions such as Asia.

Artfinder is the art marketplace creating a world where art benefits everyone. Artfinnder connects art lovers with independent artists around the world. When you buy art from Artfinder you support independent artists in over 100 countries, helping them to make a living from art. Artfinder is the first Certified B Corporation in the art world, balancing social purpose and environmental responsibility with purpose and profit. • 600,000+ subscribers around the world • 10,000+ artists and galleries internationally • 500,000+ artworks in categories including painting, printmaking, photography, sculpture, drawing and collage

Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.

UroMems SAS, founded in 2011 and based in Grenoble, France, specializes in the design, development, and commercialization of implantable medical devices. The company has created the MyoElectroMechanical System, an electronic artificial urinary sphincter (eAUS) aimed at treating severe urinary incontinence. This innovative device functions by increasing urethral pressure during physically demanding activities and decreasing it when such activities are not taking place, thereby addressing a significant clinical need that affects patients' quality of life. UroMems is dedicated to providing solutions that target specific health challenges faced by individuals with this condition.

Heliatek GmbH, based in Dresden, Germany, specializes in the development and production of organic solar films and photovoltaic cells. Its flagship product, HeliaSol, is an organic photovoltaics (OPV) solution that can be applied to various surfaces, making it suitable for building retrofitting, automotive applications, and other innovative projects. Heliatek caters to the building and construction material sector, as well as automotive manufacturers, offering tailored products like HeliaFilm for integration into façade and roofing systems. The company is recognized as a leader in organic photovoltaics, leveraging its ultra-light and flexible technology to provide sustainable energy solutions. Established in 2006, Heliatek has formed strategic partnerships with companies such as AGC Glass Europe and Reckli China, and it employs around 160 people across its facilities in Germany. The research and development of its technologies have received support from the Free State of Saxony, the Federal Republic of Germany, and the European Union.

iOmx Therapeutics focuses on the development of first-in-class cancer therapeutics addressing novel immune checkpoint modulators on tumor cells. By systematically screening human tumor cells, the Company has already identified a number of novel targets and analyzed their mode of action. The Company was founded on the successful concept of cancer immune-checkpoint therapy, which works by breaking down the inherent resistance mechanisms of tumors against immune attack. Immune resistance of tumors is often mediated by cell surface molecules that stimulate immune-inhibitory receptors on T cells. Reactivating the host immune response by neutralizing these negative interactions is the idea behind cancer immune-checkpoint therapy.

Rigontec GmbH is a biopharmaceutical company that develops RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The company develops ImOl100, a compound stimulating the immune receptor retinoic acid-inducible gene I, which recognizes viral RNA. Its ImOl100 is also a minimal mimic of naturally occurring 3pRNA, a motif typically occurring in viral RNAs. The company’s compounds avoid the pitfalls of cancer vaccines, checkpoint inhibitors, and therapeutics based on the identification of tumor antigens. Rigontec GmbH was founded in 2014 and is based in Planegg, Germany. As of October 26, 2017, Rigontec GmbH operates as a subsidiary of Merck & Co., Inc.

Jellynote is the go-to-destination for over 1 million aspiring musicians; a loyal community who enjoy sheets, tabs and chords, original video content and the opportunity to connect with one-another in the Jellynote universe. Jellynote has developed all of its proprietary technology in-house, delivering an intuitive AI-powered edtech platform to its fans. Jellynote sells premium subscriptions and generates revenue from ads. Jellynote offers over 400,000 songs that you can be played to learn through original artist video master classes, video tutorials, sheets, tabs, chords and instrument view for a wide range of instruments. The game mode provides instant feedback and social mode connects musicians share their tastes in music. The Jellynote universe demonstrates how music can connect people in a world that is getting more and more divided. Available on Smartphone and desktop.

Festicket is an online platform that enables music fans to discover and book tickets and travel packages for music festivals around the globe. By offering a seamless end-to-end experience, Festicket serves as an efficient marketplace for over 1,000 music festivals across 40 countries. The platform connects users with a network of 2,000 suppliers, facilitating accommodation and travel arrangements tailored for festivalgoers. This service caters to the needs of live music enthusiasts, allowing them to plan and enjoy their festival experiences with ease.

Social network and utility app for youth soccer players who use Tonsser every week to keep track of their stats, improve their player rating, be inspired on how to improve and engage with their community.

EndoStim, Inc., a medical device company, develops and commercializes neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Its solutions cover treatment for GERD through electrical stimulation. The company distributes its products throughout Europe, Asia, and Latin America. EndoStim was founded in 2009 and is based in Dallas, Texas.

Workframe offers a workflow optimization platform specifically designed for the commercial real estate industry. This web-based software application enables large corporate tenants, landlords, brokers, and service providers to enhance their operational efficiency by gaining visibility into their workflows. It automates the assignment of critical tasks, accelerates project delivery, and provides real-time updates, which helps in streamlining communication and collaboration. By eliminating time-consuming follow-ups and presenting actionable data, Workframe empowers users to recognize trends, share ideas, and proactively manage risks across various projects, ultimately driving cost savings and improving overall productivity.

Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

Onfido Limited specializes in identity verification software solutions that utilize artificial intelligence to authenticate users' identities. The company’s technology verifies government-issued IDs and compares them with users' facial biometrics to determine authenticity. Onfido's services are essential for applications such as Know Your Customer (KYC), user onboarding, and fraud detection, and are utilized across various sectors including financial services, marketplaces, gaming, transport, retail, and e-commerce. With a global client base of over 1,500 organizations, Onfido assists businesses in enhancing user onboarding processes while minimizing risks. Established in 2010 and headquartered in London, Onfido has expanded its operations with offices in major cities like San Francisco, New York, and Paris, among others. The company's commitment to secure and seamless identity verification aims to transform access to services ranging from banking to hospitality.

Mapillary AB operates a street-level imagery platform that utilizes collaboration, cameras, and computer vision to enhance mapping processes. Founded in 2013 and based in Malmö, Sweden, the company enables users to collect and share images from various cameras, which are then combined to create a comprehensive visual representation of the world. This imagery supports the development of updated maps and facilitates advancements in urban planning and the automotive industry. With contributions from individuals and organizations worldwide, Mapillary has amassed over 500 million images, making this data accessible for various clients and partners, including the World Bank, HERE, and Toyota Research Institute. As of June 2020, Mapillary operates as a subsidiary of Facebook, Inc.

Import.io Ltd is a SaaS company that specializes in Web Data Integration, enabling users to transform extensive web data into structured, machine-readable formats. Founded in 2012 and headquartered in London, with an additional office in Los Gatos, California, the company offers a suite of products including Import.io Extract for automated web extraction, Import.io Insights for data monitoring and visualization, Import.io API for system integration, and Import.io Transform for data formatting. Its solutions support various applications such as competitor price monitoring, MAP compliance, product matching, and customer sentiment analysis. Import.io serves over 850 clients by providing high-quality web data from millions of online sources, thereby enhancing business insights and competitive advantages.

AMBOSS is a medical technology company with offices in New York, Berlin and Cologne. Its knowledge platform has fundamentally changed the way medical know-how is acquired and utilized at the point-of-care. Students use the interactive library and high-yield question bank for general study and exam preparation, while doctors rely on AMBOSS to make effective clinical decisions guided by evidence-based recommendations. Founded in 2012 by doctors for doctors, the company’s international team has grown to over 200 physicians, scientists and software engineers, all striving to better serve doctors around the world. Today, more than half a million healthcare professionals in over 180 countries rely on AMBOSS.

Zopa Limited operates an online marketplace lending platform in the United Kingdom, facilitating unsecured loans directly between borrowers and lenders, thereby bypassing traditional banks. Established in 2004 and headquartered in London, Zopa categorizes borrowers into distinct credit grades, allowing lenders to make tailored offers based on these ratings. The platform supports various loan purposes, including car loans, debt consolidation, home improvements, and wedding expenses. Zopa manages essential services such as credit checks, legal documentation, and collections, while also mitigating lender risk through features like monthly direct debit repayments and allowing fractional lending. The company generates revenue by charging borrowers a fixed fee and levying an annual fee on lenders. Zopa has received multiple accolades for its innovative approach and commitment to customer service, positioning itself as a key player in the peer-to-peer lending market.

NEUWAY Pharma GmbH had been founded in April 2014 as the first spin-off from Life Science Inkubator GmbH. NEUWAY is focusing on the preclinical and clinical development of innovative therapeutics for treatment of orphan brain diseases based on its proprietary CNS drug delivery platform. The company also intends to partner its drug delivery technology for other CNS indications.

4SC discovers and develops targeted, small-molecule drugs for the treatment of cancer and autoimmune diseases in indications with high unmet medical needs. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious, and provide a better quality of life.

Soundtrack Your Brand is a Spotify joint venture and the exclusive provider of Spotify Business and Spotify Enterprise. We connect brands and fans, and our vision is to grow the music market and thereby support artists, so that they can give the world more great music

At Latana, we believe there is a better way to do brand tracking. We believe that brand and marketing leaders no longer have to base campaigns on guesswork, spending trillions and not sure at the end if it was worth it. We are passionate about bringing reliable data to the world of brand, finally providing a platform for brand marketing similar to what Google Analytics has been providing for other marketing channels for years. We unravel one of the least understood areas of marketing so you don't have to. Latana is here to help you grow.

Dalia Research GmbH, founded in 2013 and based in Berlin, Germany, specializes in developing online software solutions for market and opinion research. The company offers a product called Samplive, which facilitates smart data collection through various applications, mobile websites, and social media platforms. Dalia operates in over 100 countries, utilizing the app economy and advanced data science techniques to distribute millions of micro-surveys worldwide. This approach enables the collection and analysis of real-time data on consumer attitudes, public opinion, and market trends. With a diverse team from 19 different countries, Dalia Research aims to generate insights that enhance the understanding of global audiences.

Dalia Research GmbH, founded in 2013 and based in Berlin, Germany, specializes in developing online software solutions for market and opinion research. The company offers a product called Samplive, which facilitates smart data collection through various applications, mobile websites, and social media platforms. Dalia operates in over 100 countries, utilizing the app economy and advanced data science techniques to distribute millions of micro-surveys worldwide. This approach enables the collection and analysis of real-time data on consumer attitudes, public opinion, and market trends. With a diverse team from 19 different countries, Dalia Research aims to generate insights that enhance the understanding of global audiences.

EyeEm Mobile GmbH is a photography community and platform that connects photographers with brands and media outlets. Founded in 2011 and based in Berlin, Germany, with additional teams in San Francisco and New York, EyeEm enables photographers of all skill levels to share their work, learn, and interact. The platform hosts a vast collection of over 90 million images contributed by more than 20 million photographers worldwide. EyeEm's offerings include a user-friendly smartphone application that allows photographers to showcase their images, while brands can access high-quality, curated visuals for various purposes, including advertising and digital media. The company's API further facilitates developers in accessing its extensive library of photos and albums.

Rigontec GmbH is a biopharmaceutical company that develops RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The company develops ImOl100, a compound stimulating the immune receptor retinoic acid-inducible gene I, which recognizes viral RNA. Its ImOl100 is also a minimal mimic of naturally occurring 3pRNA, a motif typically occurring in viral RNAs. The company’s compounds avoid the pitfalls of cancer vaccines, checkpoint inhibitors, and therapeutics based on the identification of tumor antigens. Rigontec GmbH was founded in 2014 and is based in Planegg, Germany. As of October 26, 2017, Rigontec GmbH operates as a subsidiary of Merck & Co., Inc.

Onfido Limited specializes in identity verification software solutions that utilize artificial intelligence to authenticate users' identities. The company’s technology verifies government-issued IDs and compares them with users' facial biometrics to determine authenticity. Onfido's services are essential for applications such as Know Your Customer (KYC), user onboarding, and fraud detection, and are utilized across various sectors including financial services, marketplaces, gaming, transport, retail, and e-commerce. With a global client base of over 1,500 organizations, Onfido assists businesses in enhancing user onboarding processes while minimizing risks. Established in 2010 and headquartered in London, Onfido has expanded its operations with offices in major cities like San Francisco, New York, and Paris, among others. The company's commitment to secure and seamless identity verification aims to transform access to services ranging from banking to hospitality.

Mapillary AB operates a street-level imagery platform that utilizes collaboration, cameras, and computer vision to enhance mapping processes. Founded in 2013 and based in Malmö, Sweden, the company enables users to collect and share images from various cameras, which are then combined to create a comprehensive visual representation of the world. This imagery supports the development of updated maps and facilitates advancements in urban planning and the automotive industry. With contributions from individuals and organizations worldwide, Mapillary has amassed over 500 million images, making this data accessible for various clients and partners, including the World Bank, HERE, and Toyota Research Institute. As of June 2020, Mapillary operates as a subsidiary of Facebook, Inc.

Hintsa Performance is a leading provider of human high performance services.They offer coaching services and digital tools to improve the life and performance of individuals, teams and entire organisations. Their mission is to guide individuals, teams and organisations to enjoy better life, and consequently better performance.

YPlan uncovers the best events every day so you can get out and Live Your City. Get the lowdown on cool dates, hidden culture and where to hang with friends. Discover, book, go – it's that simple. Flash your YPlan ticket and you're in. Founded in London in February, 2012, YPlan works directly with 3500+ event partners worldwide, has over 1.5 million users, and 1000+ 5* reviews on App Store.

Cavendish Kinetics, Inc. designs, manufactures, and markets tunable components for RF circuits for cellular handsets, laptops, netbooks, tablets, and other consumer wireless devices. It offers antenna tuners for various RF applications. The company offers its products directly to customers worldwide. Cavendish Kinetics, Inc. was founded in 1994 and is headquartered in San Jose, California with an additional office in s-Hertogenbosch, the Netherlands. As of October 4, 2019, Cavendish Kinetics, Inc. operates as a subsidiary of Qorvo, Inc.

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

ImevaX GmbH is a biopharmaceutical company based in Munich, Germany, established in 2014. The company specializes in developing targeted vaccines to address chronic and nosocomial infections, with a particular focus on immune evasion factors employed by various pathogens. Its lead candidate, IMX 101, is designed to combat Helicobacter pylori, a bacterium responsible for stomach ulcers and gastric cancer in humans. ImevaX's research highlights the role of specific bacterial factors that enable H. pylori to evade the host immune response, prompting further investigation into similar mechanisms in other infectious pathogens. The company's efforts aim to enhance treatment options and improve health outcomes for patients suffering from these persistent infections.

Rigontec GmbH is a biopharmaceutical company that develops RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The company develops ImOl100, a compound stimulating the immune receptor retinoic acid-inducible gene I, which recognizes viral RNA. Its ImOl100 is also a minimal mimic of naturally occurring 3pRNA, a motif typically occurring in viral RNAs. The company’s compounds avoid the pitfalls of cancer vaccines, checkpoint inhibitors, and therapeutics based on the identification of tumor antigens. Rigontec GmbH was founded in 2014 and is based in Planegg, Germany. As of October 26, 2017, Rigontec GmbH operates as a subsidiary of Merck & Co., Inc.

Atopix Therapeutics Limited is a clinical-stage biopharmaceutical company based in Oxford, United Kingdom, focused on drug discovery for anti-inflammatory medicines. Founded in 2012, the company develops innovative oral treatments, specifically CRTH2 antagonists, aimed at addressing asthma, chronic allergic conditions, and various atopic diseases, including atopic dermatitis and allergic rhinitis. The lead candidate from Atopix is undergoing a Phase 2 clinical trial for moderate to severe atopic dermatitis at multiple prominent dermatology centers across Europe. As of December 2016, Atopix operates as a subsidiary of Chiesi Farmaceutici S.p.A.

Heliatek GmbH, based in Dresden, Germany, specializes in the development and production of organic solar films and photovoltaic cells. Its flagship product, HeliaSol, is an organic photovoltaics (OPV) solution that can be applied to various surfaces, making it suitable for building retrofitting, automotive applications, and other innovative projects. Heliatek caters to the building and construction material sector, as well as automotive manufacturers, offering tailored products like HeliaFilm for integration into façade and roofing systems. The company is recognized as a leader in organic photovoltaics, leveraging its ultra-light and flexible technology to provide sustainable energy solutions. Established in 2006, Heliatek has formed strategic partnerships with companies such as AGC Glass Europe and Reckli China, and it employs around 160 people across its facilities in Germany. The research and development of its technologies have received support from the Free State of Saxony, the Federal Republic of Germany, and the European Union.

Ztory is a Swedish startup that gives readers access to an ever growing stockpile of magazines, children’s books and other illustrated publications for a fixed price each month. Our mission is to develop peoples interests by connecting them to the best publications on subjects they love.

Festicket is an online platform that enables music fans to discover and book tickets and travel packages for music festivals around the globe. By offering a seamless end-to-end experience, Festicket serves as an efficient marketplace for over 1,000 music festivals across 40 countries. The platform connects users with a network of 2,000 suppliers, facilitating accommodation and travel arrangements tailored for festivalgoers. This service caters to the needs of live music enthusiasts, allowing them to plan and enjoy their festival experiences with ease.

Import.io Ltd is a SaaS company that specializes in Web Data Integration, enabling users to transform extensive web data into structured, machine-readable formats. Founded in 2012 and headquartered in London, with an additional office in Los Gatos, California, the company offers a suite of products including Import.io Extract for automated web extraction, Import.io Insights for data monitoring and visualization, Import.io API for system integration, and Import.io Transform for data formatting. Its solutions support various applications such as competitor price monitoring, MAP compliance, product matching, and customer sentiment analysis. Import.io serves over 850 clients by providing high-quality web data from millions of online sources, thereby enhancing business insights and competitive advantages.

AYOXXA Biosystems GmbH is a biotechnology company based in Cologne, Germany, with additional offices in Singapore and Boston, Massachusetts. Founded in 2010, AYOXXA specializes in life science tools, particularly through its proprietary technology platform for multiplexed protein analysis. The company has developed an innovative biochip technology that enables the simultaneous measurement of multiple protein markers associated with various health conditions, including cancer, allergies, cardiovascular diseases, and infectious diseases. AYOXXA's platform utilizes an in-situ encoded bead array, facilitating the identification and quantification of proteins and biomolecular analytes. This advanced approach to biomarker analysis positions AYOXXA at the forefront of diagnostic technology, allowing for comprehensive testing in a single assay.

Nosto Solutions Oy specializes in e-commerce personalization solutions for online retailers worldwide. Founded in 2011 and headquartered in Helsinki, Finland, the company offers a platform-independent software-as-a-service (SaaS) solution that enables retailers to provide real-time personalized product recommendations throughout the shopping journey. Nosto's technology is designed to enhance the online shopping experience, making it accessible for businesses of all sizes. Their offerings include automated marketing tools such as onsite product recommendations, personalized emails, and targeted advertisements on platforms like Facebook and Instagram. Nosto has served notable clients, including brands like Angry Birds and Intersport, helping retailers increase conversion rates, customer retention, and overall store revenues. The company also has offices in key global markets, including New York, Los Angeles, Berlin, Stockholm, and London.

Definiens is the provider of image analysis and data mining solutions for quantitative digital pathology in the life sciences, diagnostic biomarkers and healthcare industries. Definiens software provides detailed readouts from whole tissue slides, cell-based assays and full body scans and allows correlating this information with data derived from other sources. By automating analysis workflows, Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and supports better decisions in research, diagnostics and therapy. Definiens’ vision is to open new fields of research, to contribute to development of personalized medicine and to significantly improve the quality of patients’ lives. Definiens is headquartered in Munich, Germany, and has offices throughout the United States.

NEUWAY Pharma GmbH had been founded in April 2014 as the first spin-off from Life Science Inkubator GmbH. NEUWAY is focusing on the preclinical and clinical development of innovative therapeutics for treatment of orphan brain diseases based on its proprietary CNS drug delivery platform. The company also intends to partner its drug delivery technology for other CNS indications.

Soundtrack Your Brand is a Spotify joint venture and the exclusive provider of Spotify Business and Spotify Enterprise. We connect brands and fans, and our vision is to grow the music market and thereby support artists, so that they can give the world more great music

Jellynote is the go-to-destination for over 1 million aspiring musicians; a loyal community who enjoy sheets, tabs and chords, original video content and the opportunity to connect with one-another in the Jellynote universe. Jellynote has developed all of its proprietary technology in-house, delivering an intuitive AI-powered edtech platform to its fans. Jellynote sells premium subscriptions and generates revenue from ads. Jellynote offers over 400,000 songs that you can be played to learn through original artist video master classes, video tutorials, sheets, tabs, chords and instrument view for a wide range of instruments. The game mode provides instant feedback and social mode connects musicians share their tastes in music. The Jellynote universe demonstrates how music can connect people in a world that is getting more and more divided. Available on Smartphone and desktop.

Opvizor GmbH develops a cloud-based expert system, Opvizor which detects VMware configuration and operating issues within uploaded protocol files, configuration, event, and performance data. It discovers system integrity issues and helps to harden client’s system security; and provides administrators with security report, issues report, health check, and snapshot report. The company was founded in 2012 and is based in Vienna, Austria.

Dacuda is a computer vision company that redefines the capabilities of cameras with real-time 2D and 3D algorithms. As the leading pioneer in software 3D camera technology, Dacuda's mission is to bring 3D capturing to every consumer by making 3D content creation as easy as taking a video. Dacuda's software 3D camera helps scale existing 3D use cases to consumers with app-based scanning and enables novel experiences for Augmented and Virtual Reality headsets. Dacuda is headquartered in Zurich, Switzerland, with locations in Palo Alto, California and Shanghai, China.. Awards include: Venture Leaders Asia 2014, Gartner Cool Vendor 2013, Entrepreneur of the Year 2012 by Ernst & Young, HEC Prix Strategis 2012, Swiss Economic Award 2011, HSG Entrepreneur of the Year 2011, Swiss Innovation Prize by IDEE SUISSE, Venture Leaders 2010, Venture Kick, ETH Spin-Off Label, CTI Start-up Label

invendo medical GmbH is a German company that specializes in the development, manufacturing, and distribution of sterile, single-use, robotically-assisted endoscopy products for gastroenterology and GI surgery. Its flagship product, the invendoscopy E200 System, includes a sterile colonoscope, a handheld control unit, and a supply and processing unit. By focusing on innovation beyond just optical enhancements, the company aims to improve patient compliance and increase procedure volumes. Founded in 2001 and based in Weinheim, Germany, invendo medical serves healthcare providers across the United States and Europe. The company, which was previously known as STM Medizintechnik GmbH, rebranded in 2006 and operates as a subsidiary of Ambu A/S.

GLO AB is a company dedicated to developing and commercializing advanced LED display products utilizing nanotechnology, with its origins rooted in over a decade of research at Lund University. Founded in 2005 and headquartered in Lund, Sweden, GLO also operates a facility in Sunnyvale, California, where it conducts research and pilot fabrication. The company specializes in direct-emitting red, green, and blue microLED products, catering to various sectors including displays, illumination, and automotive applications. GLO's innovative technology allows for the creation of efficient and stable RGB emitters from a single material system, addressing limitations of traditional LED technology. This breakthrough enables superior color stability and the potential for high-quality white LEDs without phosphor conversion. With over 175 patents in the US, Europe, and Asia, GLO is focused on strengthening its intellectual property and advancing its position in the LED market, particularly in fast-growing regions such as Asia.